Self-inactivating alpharetroviral vectors with a split-packaging design.
about
The interferon-inducible antiviral protein Daxx is not essential for interferon-mediated protection against avian sarcoma virus.Genome-wide analysis of alpharetroviral integration in human hematopoietic stem/progenitor cells.Gammaretroviral vectors: biology, technology and applicationPerinatal gene transfer to the liver.Alpharetroviral self-inactivating vectors: long-term transgene expression in murine hematopoietic cells and low genotoxicity.An assessment of the effects of ectopic gp91phox expression in XCGD iPSC-derived neutrophils.Alpharetroviral vector-mediated gene therapy for X-CGD: functional correction and lack of aberrant splicing.Restriction of diverse retroviruses by SAMHD1.Development of gene therapy for blood disorders: an update.Current progress on gene therapy for primary immunodeficiencies.The long and winding road that leads to a cure for epidermolysis bullosa.Cancer gene discovery: exploiting insertional mutagenesis.Alpharetroviral vectors: from a cancer-causing agent to a useful tool for human gene therapy.Efficient generation of gene-modified human natural killer cells via alpharetroviral vectors.Directed evolution of a recombinase that excises the provirus of most HIV-1 primary isolates with high specificity.The retroviral vector family: something for everyone.Detailed comparison of retroviral vectors and promoter configurations for stable and high transgene expression in human induced pluripotent stem cells.Application of Droplet Digital PCR for Estimating Vector Copy Number States in Stem Cell Gene TherapyGeneration of Genetically Engineered Precursor T-Cells From Human Umbilical Cord Blood Using an Optimized Alpharetroviral Vector Platform.Genetic Modification of T Cells.
P2860
Q33726203-1BE817C2-FF0F-47FC-9C96-E6FC21911CC1Q33891707-5453185E-6FA7-4ED0-8C4E-D467416DFEE9Q34223822-1A499125-D00B-47F2-BE3F-11723C8DFEE3Q35238390-14003713-F72A-42A6-BAFF-554AC0140642Q35939492-F8575F8B-D090-4487-A739-BD92B20C1E68Q36358611-86CA0EB5-6A4B-4E0B-AF45-FBCFD7EDDB70Q36659242-63EB8205-3074-419F-A640-BA9A631CF009Q36707281-7F21B61A-AC1B-4129-997E-83FD044E0E85Q37132611-A5BCE921-E6E0-4804-988C-64C4C6CA93AAQ38110363-E493DBE8-326F-45EA-9945-31208015C9BBQ38119245-AD5B249A-7BD5-4E2F-BD60-D31E1B95AF35Q38127512-41CB3FE2-DFC9-45DE-9211-02BA8436C1D2Q38285765-E286A651-B3DD-4258-9BD3-58B10AED3FF1Q38841469-E88CAA7D-6AA8-4E20-A065-6804FB6EAECCQ39979692-00460D88-EBBF-463E-BC28-6EBF6E32F29CQ40100053-C3B9A5D7-0C07-4654-8F8B-EF8B84644525Q40272131-340DC2F1-B608-4423-9C86-6F5DD28D0CDCQ40414488-4EAF4176-43C8-44A8-A900-881F7943EC08Q40772331-6D1B8463-051D-48E2-8728-ADE5B715B038Q54385319-BF8F71E6-552A-45C8-925C-AA2CE8D06B74
P2860
Self-inactivating alpharetroviral vectors with a split-packaging design.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Self-inactivating alpharetroviral vectors with a split-packaging design.
@en
Self-inactivating alpharetroviral vectors with a split-packaging design.
@nl
type
label
Self-inactivating alpharetroviral vectors with a split-packaging design.
@en
Self-inactivating alpharetroviral vectors with a split-packaging design.
@nl
prefLabel
Self-inactivating alpharetroviral vectors with a split-packaging design.
@en
Self-inactivating alpharetroviral vectors with a split-packaging design.
@nl
P2093
P2860
P356
P1433
P1476
Self-inactivating alpharetroviral vectors with a split-packaging design.
@en
P2093
Christopher Baum
Julia D Suerth
Melanie Galla
Tobias Maetzig
P2860
P304
P356
10.1128/JVI.00182-10
P407
P577
2010-04-21T00:00:00Z